We are live on ! Find out more
GALT icon

Galectin Therapeutics
GALT

62 hedge funds and large institutions have $13M invested in Galectin Therapeutics in 2014 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 16

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% less funds holding

Funds holding: 63 → 62 (-1)

40% less capital invested

Capital invested by funds: $21.5M → $13M (-$8.5M)

98% less call options, than puts

Call options by funds: $15K | Put options by funds: $679K

Holders
62
Holders Change
-1
Holders Change %
-1.59%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
22
Reduced
16
Closed
8
Calls
$15K
Puts
$679K
Net Calls
-$664K
Net Calls Change
+$164K

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$332K
2
Morgan Stanley
Morgan Stanley
New York
+$328K
3
BFA
BlackRock Fund Advisors
California
+$309K
4
VKH
Virtu KCG Holdings
New York
+$176K
5
FIM
Freedom Investment Management
Connecticut
+$174K

Top Sellers

Rank Fund Capital Flow
1
CCA
Catalyst Capital Advisors
New York
-$3.4M
2
CAM
Cormorant Asset Management
Massachusetts
-$612K
3
ARTA
A.R.T. Advisors
New York
-$186K
4
BCA
Benchmark Capital Advisors
New York
-$148K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$141K
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teachers Advisors
New York
$88K – – –
SIP
27
Stoneridge Investment Partners
Pennsylvania
$87K +$111K +25,095 New
California Public Employees Retirement System
28
California Public Employees Retirement System
California
$84K – – –
Millennium Management
29
Millennium Management
New York
$84K +$40.5K +9,157 +60%
Commonwealth Equity Services
30
Commonwealth Equity Services
Massachusetts
$70K +$384 +87 +0.4%
SWP
31
Stratos Wealth Partners
Ohio
$66K – – –
State Board of Administration of Florida Retirement System
32
State Board of Administration of Florida Retirement System
Florida
$64K – – –
RG
33
Rathbones Group
United Kingdom
$57K – – –
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$50K +$1.88K +425 +3%
NFA
35
Nationwide Fund Advisors
Ohio
$49K – – –
Goldman Sachs
36
Goldman Sachs
New York
$49K +$13.3K +2,999 +27%
VOYA Investment Management
37
VOYA Investment Management
Georgia
$47K – – –
RCM
38
Rotella Capital Management
Washington
$47K +$59.7K +13,505 New
AIG
39
American International Group
New York
$42.8K +$2.44K +552 +5%
Bank of America
40
Bank of America
North Carolina
$37K -$26.1K -5,904 -36%
PPA
41
Parametric Portfolio Associates
Washington
$35K -$6.79K -1,536 -13%
TRCT
42
Tower Research Capital (TRC)
New York
$28K +$5.21K +1,180 +17%
GT
43
Glenmede Trust
Pennsylvania
$27K -$35.8K -8,100 -50%
Creative Planning
44
Creative Planning
Kansas
$27K – – –
BA
45
BlackRock Advisors
Delaware
$26K – – –
Simplex Trading
46
Simplex Trading
Illinois
$25K +$31.4K +7,103 New
Citadel Advisors
47
Citadel Advisors
Florida
$24K -$57.9K -13,112 -66%
PAM
48
Panagora Asset Management
Massachusetts
$18K – – –
Wells Fargo
49
Wells Fargo
California
$16K +$367 +83 +2%
UBS Group
50
UBS Group
Switzerland
$12K +$15.5K +3,514 New
1
2
3

GALT Hedge Fund Activity: Q4 2014 in Review

62 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2014, worth a combined $13M — down 40% from $21.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new GALT positions and 8 closed out — a net gain of 1 holder — while 22 added to existing stakes and 16 trimmed.

The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $332K. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $3.4M sold.

  • 62 institutional investors held Galectin Therapeutics (GALT) as of Q4 2014, down from 63 in Q3 2014.
  • Funds reported $13M of Galectin Therapeutics stock for Q4 2014, down 40% quarter-over-quarter.
  • 9 funds opened new Galectin Therapeutics positions in Q4 2014 and 8 closed out, a net change of +1 holder.
  • The largest Galectin Therapeutics buyer in Q4 2014 was D.E. Shaw & Co, an estimated $332K added.
  • The largest Galectin Therapeutics seller in Q4 2014 was Catalyst Capital Advisors, an estimated $3.4M sold.

Based on aggregated 13F filings for Q4 2014.